Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple ultrasound reveal hidden gut damage in scleroderma?

NCT ID NCT07171437

Knowledge-focused Sponsor: Esraa Moustafa Mohammed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will use Doppler ultrasound to measure blood flow in the gut arteries of 74 people with systemic sclerosis (scleroderma) and compare them to healthy volunteers. The goal is to see if changes in blood flow relate to digestive symptoms and other organ problems. This is an observational study, meaning no treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand and detect gut problems in scleroderma patients using a simple ultrasound.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct benefit for participants, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 18 years or older classified as systemic sclerosis (SSc) according to ACR/EULAR 2013 classification criteria subject to in- hospital care due to SSc at Assiut University Hospital will be undergoing to clinical assessment, laboratory assessment and imaging

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged 18 years or older. 2. Patients classified as systemic sclerosis (SSc) according to ACR/EULAR 2013 classification criteria. 3. Patients who consented to undergo Doppler ultrasound (DUS) assessment of the splanchnic vessels. Exclusion Criteria: 1. Patients younger than 18 years old. 2. Pregnancy or lactation. 3. Patients with overlapping autoimmune diseases (e.g., lupus, rheumatoid arthritis). 4. Patients with known gastrointestinal disorders not related to systemic sclerosis (e.g., inflammatory bowel disease, celiac disease). 5. Patients with a history of major gastrointestinal surgery (e.g., bowel resection). 6. Patients with diabetes mellitus (due to its independent effects on vascular flow). 7. Presence of severe comorbidities (e.g., end-stage renal disease, decompensated heart failure).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic sclerosis associated git vasculopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assiut University, Assiut, 71111

    Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.